NASDAQ:HSTM - Nasdaq - US42222N1037 - Common Stock - Currency: USD
HealthStream (HSTM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
HealthStream (HSTM) delivered earnings and revenue surprises of -12.50% and 1.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BLIN
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HealthStream (NASDAQ:HSTM) just reported results for the first quarter of 2024....
Dayforce's Q1 performance is expected to have benefited from strong client retention, AI-led platform enhancements and rising recurring revenue per customer.
DoorDash (DASH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: DASH
Alphabet (GOOGL) delivered earnings and revenue surprises of 39.11% and 1.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Johnson & Johnson’s electrophysiology unit struggled in the first quarter, as the company chases Medtronic and Boston Scientific in the red-hot pulsed field ablation market.
HealthStream (HSTM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HSTM stock results show that HealthStream beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.